ETC-1002 regulates immune response,leukocyte homing,and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK |
| |
Authors: | Sergey Filippov Stephen L. Pinkosky Richard J. Lister Catherine Pawloski Jeffrey C. Hanselman Clay T. Cramer Rai Ajit K. Srivastava Timothy R. Hurley Cheryl D. Bradshaw Mark A. Spahr Roger S. Newton |
| |
Affiliation: | Esperion Therapeutics Inc., Plymouth, MI, 48170 |
| |
Abstract: | ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates levels of hsCRP, a clinical biomarker of inflammation. Anti-inflammatory properties of ETC-1002 were further investigated in primary human monocyte-derived macrophages and in in vivo models of inflammation. In cells treated with ETC-1002, increased levels of AMP-activated protein kinase (AMPK) phosphorylation coincided with reduced activity of MAP kinases and decreased production of proinflammatory cytokines and chemokines. AMPK phosphorylation and inhibitory effects of ETC-1002 on soluble mediators of inflammation were significantly abrogated by siRNA-mediated silencing of macrophage liver kinase B1 (LKB1), indicating that ETC-1002 activates AMPK and exerts its anti-inflammatory effects via an LKB1-dependent mechanism. In vivo, ETC-1002 suppressed thioglycollate-induced homing of leukocytes into mouse peritoneal cavity. Similarly, in a mouse model of diet-induced obesity, ETC-1002 restored adipose AMPK activity, reduced JNK phosphorylation, and diminished expression of macrophage-specific marker 4F/80. These data were consistent with decreased epididymal fat-pad mass and interleukin (IL)-6 release by inflamed adipose tissue. Thus, ETC-1002 may provide further clinical benefits for patients with cardiometabolic risk factors by reducing systemic inflammation linked to insulin resistance and vascular complications of metabolic syndrome. |
| |
Keywords: | AMP-activated protein kinase mitogen-activated protein kinases liver kinase B1 macrophages/monocytes cytokines adipose tissue cardiometabolic risk factors drug therapy hypolipidemic drugs |
本文献已被 ScienceDirect 等数据库收录! |
|